Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cancer

Project Details

Description

DESCRIPTION (provided by applicant): Pancreatic cancer (PC) remains one of the least treatable cancers, with high metastatic propensity, poor response to existing therapies and short survivals that have not improved substantially over several decades. Most PC patients will die within the first year after diagnosis and
StatusFinished
Effective start/end date12/5/1411/30/16

Funding

  • National Cancer Institute: $203,337.00
  • National Cancer Institute: $155,875.00

ASJC

  • Oncology
  • Cancer Research

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.